Dr. John studies the malaria parasite, Plasmodium falciparum, to understand its basic molecular and cellular biology and functions of its specific metabolic pathways — what the parasite needs to make and why it needs to make it — to identify new antimalarial drug targets and develop new diagnostics.
Dr. Coffin’s research interests focus on the epidemiology and prevention of healthcare-associated infections in the pediatric population. She also investigates the epidemiology of pediatric respiratory viral infections, with a particular emphasis on influenza.
Dr. Steenhoff is medical director of the Global Health Center at Children's Hospital. He serves as a global health advocate for children, seeking to optimize mutually beneficial partnerships between clinical and academic institutions in diverse settings.
Dr. Silverman studies the fundamental aspects of early-life commensal microbes that influence immune system development and function. He discovered that the MHC-II E molecule prevents type 1 diabetes by shaping the intestinal microbiota early in life.
Dr. Feemster's research includes vaccine acceptance among parents and immunization providers, community-based interventions to improve vaccine uptake, neighborhood factors associated with the incidence of pertussis and influenza, and healthcare-associated respiratory infection in the pediatric ambulatory setting.
Dr. Fisher's research focuses on infections in children with immunocompromising conditions. He is particularly interested in infections in children with cancer and serves as the chair of the Infectious Disease Domain within the Children’s Oncology Group.
Dr. Zaoutis is a pediatrician trained in infectious disease and epidemiology with a robust research program focused on the epidemiology, prevention, and treatment of healthcare acquired infections; antimicrobial resistance; and antimicrobial use.
The research interests of Dr. Downes focus on antimicrobial clinical pharmacology and pharmacoepidemiology in children with a goal to identify novel approaches to optimize efficacy, minimize toxicity, and limit antimicrobial resistance from antibiotics.
Dr. Green’s long-term goal is to elucidate the sources of DNA damage in childhood leukemia in order to develop better therapies and ultimately improve outcomes. She specifically studies the intersection of immune responses to viral infection and genome instability, working closely with virologists, oncologists, and geneticists at Children’s Hospital of Philadelphia, Penn, and nationwide.